Paper Details 
Original Abstract of the Article :
Buprenorphine is a partial mu-opioid agonist available as a transdermal patch for use in patients with chronic pain. Transdermal products can be associated with application site reactions (ASRs). The incidence of ASRs to the buprenorphine transdermal patch (BTP) have been described as low and seldom...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1080/15360288.2022.2051676

データ提供:米国国立医学図書館(NLM)

Application Site Reactions from the Buprenorphine Transdermal Patch

This study investigates the occurrence of application site reactions (ASRs) associated with the buprenorphine transdermal patch (BTP), a common medication for chronic pain. The researchers report a series of four patients who developed ASRs to the BTP, leading to treatment discontinuation or a switch to buprenorphine buccal films. They found that ASRs were more likely to occur at higher patch strengths, suggesting a potential dose-response relationship and a possible allergic reaction. This study provides valuable insights into the potential adverse effects of the BTP.

Application Site Reactions to Buprenorphine Patches

The study's findings highlight the potential for application site reactions (ASRs) to the buprenorphine transdermal patch (BTP), particularly at higher patch strengths. The researchers report a series of cases where ASRs led to treatment discontinuation or a switch to alternative medications. This information is important for healthcare providers to consider when prescribing BTP and for patients to be aware of potential side effects.

Managing Pain Without Side Effects

Imagine a camel carrying heavy loads across a rugged desert terrain. Just as the camel relies on its strength and endurance to overcome the challenges, individuals with chronic pain need effective pain management solutions. This study emphasizes the importance of carefully monitoring for ASRs when using buprenorphine patches. Understanding these potential side effects can help ensure that patients receive safe and effective pain relief.

Dr.Camel's Conclusion

This case series provides valuable insights into the potential for application site reactions (ASRs) associated with the buprenorphine transdermal patch (BTP). The findings suggest a potential dose-response relationship and a possible allergic reaction, highlighting the importance of monitoring for ASRs and considering alternative medications if they occur. Further research is needed to fully understand the mechanisms behind ASRs to the BTP.
Date :
  1. Date Completed 2022-05-02
  2. Date Revised 2022-05-02
Further Info :

Pubmed ID

35332848

DOI: Digital Object Identifier

10.1080/15360288.2022.2051676

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.